Eurofins Scientific SE: Over 10% Organic Growth in the First Nine Months of 2016
October 20 2016 - 1:30AM
Business Wire
- Revenues grew 25% in Q3 2016 to EUR
629m, bringing revenues in the first nine months of 2016 (NM 2016)
to EUR 1,837m, a 36% increase compared to NM 2015.
- Organic growth in NM 2016 was over
10% as the Group continued to exceed its 5% organic growth
objective in the third quarter, despite strong comparable growth in
Q3 2015.
- Year to date, Eurofins has completed
24 acquisitions for total annualised revenues of over EUR
190m.
- Growth trends remain positive in
most of Eurofins’ businesses and geographies.
Regulatory News:
Eurofins Scientific SE (Paris:ERF):
Comments from the CEO, Dr. Gilles Martin: “Eurofins’
performance in the first nine months of 2016 reflects the continued
positive trends as well as the Group’s increasing scale in many of
its markets. The strength in underlying fundamentals, in addition
to the expected benefits from our Group-wide investment programs
and M&A opportunities, remain supportive of Eurofins’ positive
future development towards its EUR 4bn 2020 revenue objective.
Having significantly reduced its leverage in Q2 and Q3 of 2016
through two equity offerings, Eurofins is very well positioned to
take advantage of opportunities in its markets, but intends to
remain conservative and long-term oriented in its investments.”
EUR m
NM 2016 NM 2015 % Growth
of which organic of which FX
Eurofins Group Revenues
1,837 1,347 36% >10%
-0.7%
Organic growth remained well above Group objective in the third
quarter, despite the strong comparable organic growth in the same
period in 2015, when organic growth started to accelerate
significantly. For NM 2016, organic growth remained robust in most
of the Group’s businesses, notably in North America, which now
comprises 32% of Group revenues, where double-digit organic growth
is underpinned by industry tailwinds. In France, organic growth
remains well above Group objective despite the inclusion of the
clinical testing scope, which has a different growth profile. The
double-digit organic growth in Germany is a demonstration of the
benefits of the Group’s scale in this market. Overall, the strong
performance year to date allows the Group to remain very positive
about its medium-term outlook.
For more information, please visit
www.eurofins.com
Organic growth for a given period (Q1, Q2, Q3, Half Year, Nine
Months or Full Year) - non-IFRS measure calculating the growth in
revenues during that period between 2 successive years for the same
scope of businesses using the same exchange rates but excluding
discontinued operations.
For the purpose of organic growth calculation for year Y, the
relevant scope used is the scope of businesses that have been
consolidated in the Group's income statement of the previous
financial year (Y-1). Revenue contribution from companies acquired
in the course of Y-1 but not consolidated for the full year are
adjusted as if they had been consolidated as from 1st January Y-1.
All revenues from businesses acquired since 1st January Y are
excluded from the calculation.
Notes for the editor:Eurofins – a global leader in
bio-analysis
Eurofins believes it is the world leader in food, environment
and pharmaceutical products testing and that it is also one of the
global independent market leaders in certain testing and laboratory
services for agroscience, genomics and discovery pharmacology and
for supporting clinical studies. In addition, Eurofins is one of
the significant emerging players in specialty clinical diagnostic
testing in Europe and the USA.
With 25,000 staff in more than 250 laboratories across 39
countries, Eurofins offers a portfolio of over 130,000 validated
analytical methods for evaluating the safety, identity,
composition, authenticity, origin, traceability and purity of
biological substances and products, as well as for innovative
clinical diagnostic. The Group provides its customers with
high-quality services, accurate results on time and expert advice
by its highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by
expanding both its technology portfolio and its geographic reach.
Through R&D and acquisitions, the Group draws on the latest
developments in the field of biotechnology and analytical chemistry
to offer its clients unique analytical solutions and the most
comprehensive range of testing methods.
As one of the most innovative and quality oriented international
players in its industry, Eurofins is ideally positioned to support
its clients’ increasingly stringent quality and safety standards
and the expanding demands of regulatory authorities and healthcare
practitioners around the world.
The shares of Eurofins Scientific are listed on the Euronext
Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg
ERF FP).
Important disclaimer:This press release contains
forward-looking statements and estimates that involve risks and
uncertainties. The forward-looking statements and estimates
contained herein represent the judgement of Eurofins Scientific’
management as of the date of this release. These forward-looking
statements are not guarantees for future performance, and the
forward-looking events discussed in this release may not occur.
Eurofins Scientific disclaims any intent or obligation to update
any of these forward-looking statements and estimates. All
statements and estimates are made based on the information
available to the Company’s management as of the date of
publication, but no guarantee can be made as to their validity.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161019006158/en/
Eurofins Investor RelationsPhone: +32-2-766 1620E-mail:
ir@eurofins.com
Enerplus (NYSE:ERF)
Historical Stock Chart
From Mar 2024 to Apr 2024
Enerplus (NYSE:ERF)
Historical Stock Chart
From Apr 2023 to Apr 2024